Reproxalap for the Treatment of Dry Eye Disease
Author:
Abstract
Reproxalap is a reactive aldehyde species inhibitor. This article investigates reproxalap’s ability to control ocular inflammation in non-infectious uveitis, allergic conjunctivitis and dry eye disease. Clinical trials for reproxalap were reviewed for efficacy and tolerability. Reproxalap appears to be an effective treatment for dry eye disease, with satisfactory tolerability.
Funder
This article is published under the Creative Commons Attribution Non-commercial License.
Publisher
Touch Medical Media, Ltd.
Reference31 articles.
1. Labib BA, Chigbu DI. Therapeutic targets in allergic conjunctivitis. Pharmaceuticals (Basel). 2022;15:547. DOI: 10.3390/ph15050547
2. Verlato G, Corsico A, Villani S, et al. Is the prevalence of adult asthma and allergic rhinitis still increasing? Results of an Italian study. J Allergy Clin Immunol. 2003;111:1232–38. DOI: 10.1067/mai.2003.1484
3. Villegas BV, Benitez-Del-Castillo JM. Current knowledge in allergic conjunctivitis. Turk J Ophthalmol. 2021;51:45–54. DOI: 10.4274/tjo.galenos.2020.11456
4. Pflugfelder SC, Stern ME, Symposium Participants. Immunoregulation on the ocular surface: 2nd Cullen Symposium. Ocul Surf. 2009;7:67–77. DOI: 10.1016/s1542- 0124(12)70297-5
5. Forrester JV, Xu H, Kuffová L, Dick AD, McMenamin PG. Dendritic cell physiology and function in the eye. Immunol Rev. 2010;234:282–304. DOI: 10.1111/j.0105-2896.2009.00873.x
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3